Literature DB >> 16005983

Patient-based utilities for bipolar disorder-related health states.

Dennis A Revicki1, Jennifer Hanlon, Silas Martin, Laszlo Gyulai, S Nassir Ghaemi, Frances Lynch, Sally Mannix, Leah Kleinman.   

Abstract

BACKGROUND: Bipolar disorder is a psychiatric disorder which impacts patient functioning and well-being. With increasing interest in cost-effectiveness of treatments, it is necessary to provide estimates of patient's perspectives on treatment outcomes. This study estimated health state utilities for hypothetical bipolar-related health states and patient's current health from bipolar I patients.
METHODS: Clinicians completed Young Mania Rating Scale, Montgomery-Asberg Depression Rating Scale, and Global Assessment Score. Patients completed structured standard gamble (SG) utility assessment interviews, and the other patient-based measures. Interviews obtained utilities for hypothetical bipolar-related health states describing symptom severity, functioning and well-being, and treatment-related side effects.
RESULTS: Ninety-six patients were recruited from psychiatry outpatient practices. Mean utilities for inpatient states ranged from 0.12 to 0.33; outpatient mania states ranged from 0.29 to 0.64; outpatient stable states ranged from 0.53 to 0.85. Mean utility for current health was 0.80 (S.D.=0.22). Patients preferred monotherapy compared with combination therapy health states. Ordinary least squares regression indicated weight gain was associated with a 0.066 decrease in health state utilities (P=0.013). LIMITATIONS: Study sample consisted of selected stable and educated patients and small sample sizes may limit generalizability for some utilities.
CONCLUSIONS: Bipolar disorder patients are capable of participating in utility assessment and providing ratings for hypothetical health states associated with different mood stabilizer treatments.

Entities:  

Mesh:

Year:  2005        PMID: 16005983     DOI: 10.1016/j.jad.2005.03.017

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  17 in total

1.  Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Authors:  Mattias Ekman; Peter Lindgren; Carolin Miltenburger; Genevieve Meier; Julie C Locklear; Mary Lou Chatterton
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

2.  Measuring Population Health in a Large Integrated Health System to Guide Goal Setting and Resource Allocation: A Proof of Concept.

Authors:  Elizabeth R Stevens; Qinlian Zhou; Kimberly A Nucifora; Glen B Taksler; Marc N Gourevitch; Matthew C Stiefel; Patricia Kipnis; R Scott Braithwaite
Journal:  Popul Health Manag       Date:  2018-12-04       Impact factor: 2.459

3.  Patient-Important Outcomes in the Long-Term Treatment of Bipolar Disorder: A Mixed-Methods Approach Investigating Relative Preferences and a Proposed Taxonomy.

Authors:  Øystein Eiring; Magne Nylenna; Kari Nytrøen
Journal:  Patient       Date:  2016-04       Impact factor: 3.883

Review 4.  Economics of atypical antipsychotics in bipolar disorder: a review of the literature.

Authors:  Rachael L Fleurence; Julia M Dixon; Dennis A Revicki
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER).

Authors:  Rachel A Elliott; Koen D Putman; Matthew Franklin; Lieven Annemans; Nick Verhaeghe; Martin Eden; Jasdeep Hayre; Sarah Rodgers; Aziz Sheikh; Anthony J Avery
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

Review 6.  A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.

Authors:  Ifigeneia Mavranezouli; Joran Lokkerbol
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

7.  Health state utility values of high prevalence mental disorders in Australia: results from the National Survey of Mental Health and Wellbeing.

Authors:  Cathrine Mihalopoulos; Lidia Engel; Long Khanh-Dao Le; Anne Magnus; Meredith Harris; Mary Lou Chatterton
Journal:  Qual Life Res       Date:  2018-04-09       Impact factor: 4.147

8.  Predictors of health-related quality-of-life utilities among persons with posttraumatic stress disorder.

Authors:  Jason N Doctor; Lori A Zoellner; Norah C Feeny
Journal:  Psychiatr Serv       Date:  2011-03       Impact factor: 3.084

9.  Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder.

Authors:  Nadir Cheema; Sophia Frangou; Paul McCrone
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

10.  Recurrent Events Model Application in Determining the Risk Factors of Bipolar Disorder Recurrence.

Authors:  Mansour Rezaei; Seyed Reza Hashemi; Vahid Farnia; Sharmin Rahmani
Journal:  Iran J Psychiatry       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.